Showing 49 to 60 of 116 results
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
Progress
44% Bias Score
FDA Ban on Compounded GLP-1 Drugs Restricts Access for Thousands
The FDA's ban on compounded GLP-1 medications, effective this week, will restrict access for thousands of patients who rely on these lower-cost alternatives for weight loss and diabetes, despite concerns about potential shortages and insurance coverage challenges.
FDA Ban on Compounded GLP-1 Drugs Restricts Access for Thousands
The FDA's ban on compounded GLP-1 medications, effective this week, will restrict access for thousands of patients who rely on these lower-cost alternatives for weight loss and diabetes, despite concerns about potential shortages and insurance coverage challenges.
Progress
60% Bias Score
FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns
The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.
FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns
The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.
Progress
56% Bias Score
GLP-1 Receptor Agonists Show Comparable Effectiveness to Bariatric Surgery in Reducing Obesity-Related Cancer Risk
An Israeli study of 6,356 obese individuals with diabetes found that GLP-1 receptor agonists (GLP-1 RAs) and bariatric metabolic surgery showed similar low rates of obesity-related cancers, with GLP-1 RAs showing a 41% relative risk reduction compared to surgery; further research is needed to confir...
GLP-1 Receptor Agonists Show Comparable Effectiveness to Bariatric Surgery in Reducing Obesity-Related Cancer Risk
An Israeli study of 6,356 obese individuals with diabetes found that GLP-1 receptor agonists (GLP-1 RAs) and bariatric metabolic surgery showed similar low rates of obesity-related cancers, with GLP-1 RAs showing a 41% relative risk reduction compared to surgery; further research is needed to confir...
Progress
40% Bias Score
Weight Loss Injections' Rise Contributes to Weight Watchers' Bankruptcy
Simon, 34, lost 26 kg using Monjaro weight loss injections after years of failed dieting, including with Weight Watchers which has lost over a million members and filed for bankruptcy amid the rise of weight loss injections and social media.
Weight Loss Injections' Rise Contributes to Weight Watchers' Bankruptcy
Simon, 34, lost 26 kg using Monjaro weight loss injections after years of failed dieting, including with Weight Watchers which has lost over a million members and filed for bankruptcy amid the rise of weight loss injections and social media.
Progress
56% Bias Score
WeightWatchers Files for Bankruptcy, Pivots to Telehealth
WeightWatchers, facing declining revenue and an aging customer base, filed for Chapter 11 bankruptcy on Tuesday to eliminate \$1.15 billion in debt, planning to focus on its telehealth division, WeightWatchers Clinic, which saw a 57% revenue increase in the last year, and expects to exit bankruptcy ...
WeightWatchers Files for Bankruptcy, Pivots to Telehealth
WeightWatchers, facing declining revenue and an aging customer base, filed for Chapter 11 bankruptcy on Tuesday to eliminate \$1.15 billion in debt, planning to focus on its telehealth division, WeightWatchers Clinic, which saw a 57% revenue increase in the last year, and expects to exit bankruptcy ...
Progress
32% Bias Score
Weight Regain After Stopping Weight-Loss Injections: An Oxford Study
A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.
Weight Regain After Stopping Weight-Loss Injections: An Oxford Study
A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.
Progress
48% Bias Score
WeightWatchers Partners with GLP-1 Provider Amidst Financial Troubles
WeightWatchers, facing bankruptcy in the US, partners with UK GLP-1 weight-loss medication provider CheqUp, integrating its app to support users of weight-loss injections like Wegovy and Mounjaro, aiming for improved and sustainable weight loss, as demand for traditional programs declines.
WeightWatchers Partners with GLP-1 Provider Amidst Financial Troubles
WeightWatchers, facing bankruptcy in the US, partners with UK GLP-1 weight-loss medication provider CheqUp, integrating its app to support users of weight-loss injections like Wegovy and Mounjaro, aiming for improved and sustainable weight loss, as demand for traditional programs declines.
Progress
48% Bias Score
Weight-Loss Injections Show Promise in Extending Lifespans, Preventing Diseases
New weight-loss injections, GLP-1 agonists like Mounjaro and Wegovy, show promise in delaying age-related illnesses and reducing heart attack risk by half, based on a 17,000-patient trial, leading experts to suggest expanded access for up to half of Britons to improve health and longevity.
Weight-Loss Injections Show Promise in Extending Lifespans, Preventing Diseases
New weight-loss injections, GLP-1 agonists like Mounjaro and Wegovy, show promise in delaying age-related illnesses and reducing heart attack risk by half, based on a 17,000-patient trial, leading experts to suggest expanded access for up to half of Britons to improve health and longevity.
Progress
52% Bias Score
Weight-Loss Injections May Almost Halve Obesity-Related Cancer Risk
A study of 6,000 adults found that weight-loss injections, specifically GLP-1RAs, may reduce the risk of obesity-related cancers by almost 50%, a finding comparable to bariatric surgery; this discovery could lead to a new era of preventive cancer medicine.
Weight-Loss Injections May Almost Halve Obesity-Related Cancer Risk
A study of 6,000 adults found that weight-loss injections, specifically GLP-1RAs, may reduce the risk of obesity-related cancers by almost 50%, a finding comparable to bariatric surgery; this discovery could lead to a new era of preventive cancer medicine.
Progress
48% Bias Score
Weight Loss Injections Could Boost UK Economy by £4.5 Billion
Research presented at the European Congress on Obesity in Málaga estimates that providing semaglutide to eligible UK residents could boost the economy by £4.5 billion due to increased productivity among 2,660 trial participants who gained an average of 17 extra workdays annually, offsetting some of ...
Weight Loss Injections Could Boost UK Economy by £4.5 Billion
Research presented at the European Congress on Obesity in Málaga estimates that providing semaglutide to eligible UK residents could boost the economy by £4.5 billion due to increased productivity among 2,660 trial participants who gained an average of 17 extra workdays annually, offsetting some of ...
Progress
44% Bias Score
WeightWatchers Files for Bankruptcy Amidst Rise of Weight-Loss Injections
WeightWatchers filed for bankruptcy in the US due to $1.88 billion in liabilities exceeding asset value and decreased demand from the rise of weight loss injections, resulting in a $1.15 billion debt write-off while maintaining operations.
WeightWatchers Files for Bankruptcy Amidst Rise of Weight-Loss Injections
WeightWatchers filed for bankruptcy in the US due to $1.88 billion in liabilities exceeding asset value and decreased demand from the rise of weight loss injections, resulting in a $1.15 billion debt write-off while maintaining operations.
Progress
36% Bias Score
Showing 49 to 60 of 116 results